Recombinant Pardachirus marmoratus Pardaxin-1

What is the primary structure and origin of Pardaxin-1?

Pardaxin-1 is a 33-amino-acid pore-forming polypeptide toxin naturally isolated from the Red Sea Moses sole (Pardachirus marmoratus). It exhibits a characteristic helix-hinge-helix structural motif that is common in both selective antibacterial peptides and cytotoxic peptides capable of lysing both mammalian and bacterial cells . The peptide was initially identified as a marine fish toxin but has gained significant attention for its potential therapeutic applications due to its antimicrobial and antitumor properties. Recombinant production of Pardaxin-1 allows for consistent quality and structural integrity compared to extraction from natural sources, enabling more reliable experimental outcomes.

How does the structure of Pardaxin-1 contribute to its biological activities?

The unique helix-turn-helix conformation of Pardaxin-1 significantly influences its biological activities. When bound to lipopolysaccharide (LPS), Pardaxin adopts a distinctive "horseshoe" conformation that differs substantially from structures observed in lipid micelles or organic solvents . This conformational versatility allows the peptide to interact with diverse membrane compositions. The N-terminal and C-terminal domains play distinct roles in activity: the C-terminal region contributes to non-selective activity against both erythrocytes and bacteria, while modifications to the N-terminus can enhance antibacterial selectivity . Nuclear magnetic resonance (NMR) studies have revealed that the membrane orientation and interactions of Pardaxin are highly dependent on lipid bilayer compositions, with the peptide capable of forming both stable and transient pores in zwitterionic lipid vesicles .

What distinguishes Pardaxin-1 from other antimicrobial peptides?

Pardaxin-1 possesses high antibacterial activity with significantly reduced hemolytic activity toward human red blood cells (hRBCs) compared to cytotoxic peptides like melittin . Its potency is comparable to other established antimicrobial peptides such as magainin, cecropins, and dermaseptins. The key distinguishing features include:

• Structural versatility - ability to adopt different conformations depending on the membrane environment

• Selective toxicity - capability to target bacterial cells while showing reduced toxicity toward mammalian cells

• Dual functionality - demonstrates both antimicrobial and antitumor activities

• Modifiable structure - various domains can be modified to enhance specificity and potency

These properties make Pardaxin-1 particularly interesting for therapeutic development, as it offers a foundation for designing analogues with enhanced selectivity and reduced side effects .

How do modifications to the C-terminus affect Pardaxin-1's activity profile?

C-terminal modifications significantly alter Pardaxin-1's activity profile. The aminated form of Pardaxin (with an amino group at the C-terminus rather than a free carboxylate) exhibits both high hemolytic and antibacterial activity . This dual activity can be problematic for therapeutic applications due to potential toxicity to host cells. Importantly, truncation experiments involving removal of 11 amino acids from the C-terminal domain dramatically reduced hemolytic activity while maintaining antibacterial function . Furthermore, the aminated form of this truncated analogue demonstrated significantly greater potency against most bacteria tested compared to the native peptide, suggesting that the C-terminal tail is responsible for non-selective activity against both erythrocytes and bacteria . This finding provides a critical direction for designing Pardaxin-1 analogues with improved therapeutic indices.

What structural modifications enhance Pardaxin-1's selectivity toward bacterial membranes?

Several modifications have been demonstrated to enhance Pardaxin-1's selectivity toward bacterial membranes:

• N-terminal charge modification: Adding a positive charge to the N-terminus significantly increases antibacterial activity while abolishing residual hemolytic activity .

• C-terminal truncation: Removing 11 amino acids from the C-terminal domain dramatically reduces hemolytic activity while preserving antibacterial function .

• C-terminal amidation: The aminated forms of specific domains show selective activity against gram-positive bacteria. For example, the 22-amino-acid C-terminal domain and the short 11-amino-acid N-terminal domain, when aminated, demonstrated activity exclusively against gram-positive bacteria .

• α-helical content enhancement: Secondary structure determination using circular dichroism spectroscopy revealed that all aminated analogues had 25-80% more α-helical content in 40% CF₃CH₂OH/water than their non-aminated forms, correlating with increased antimicrobial activity .

These modifications provide researchers with strategies to fine-tune Pardaxin-1's selectivity profile for specific experimental or therapeutic applications.

What is the significance of the "horseshoe" conformation observed in LPS-bound Pardaxin?

The unique "horseshoe" conformation that Pardaxin adopts when bound to lipopolysaccharide (LPS) is critically important for understanding its outer membrane permeabilization mechanism . This conformation shows striking differences compared to structures determined in lipid micelles or organic solvents, suggesting environment-specific structural adaptability. Saturation transfer difference (STD) NMR experiments have identified specific residues of Pardaxin that intimately associate with LPS micelles, providing mechanistic insights into how the peptide initially interacts with the bacterial outer membrane . The horseshoe structure likely facilitates optimal positioning of key amphipathic regions for membrane penetration and pore formation, explaining how Pardaxin can disrupt the outer membrane barrier of gram-negative bacteria. This conformational knowledge is essential for designing analogues with enhanced permeabilization capabilities or for developing novel antimicrobial peptides that target specific membrane components.

What mechanisms underlie Pardaxin-1's antibacterial activity?

Pardaxin-1 employs multiple mechanisms to exert its antibacterial activity:

These mechanisms collectively contribute to Pardaxin-1's efficacy as an antimicrobial agent while suggesting specific routes for enhancing its activity or selectivity through strategic modifications.

How does Pardaxin-1 compare to other antimicrobial peptides in terms of potency and selectivity?

Pardaxin-1 demonstrates comparable potency to several established antimicrobial peptides while offering potentially superior selectivity profiles:

Pardaxin-1 shows significantly reduced hemolytic activity toward human red blood cells compared to melittin while maintaining comparable antibacterial potency . Its natural structure offers a promising foundation for modifications that can further enhance its selectivity, particularly through modifications to the C-terminal and N-terminal domains as described earlier. The peptide's versatility in adopting different conformations based on membrane environment may explain its ability to distinguish between bacterial and mammalian cell membranes. These properties make Pardaxin-1 a valuable candidate for further development as an antimicrobial agent with reduced toxicity concerns.

What cancer models have demonstrated sensitivity to Pardaxin-1 treatment?

Pardaxin-1 has demonstrated significant antitumor activity in multiple cancer models:

• Murine fibrosarcoma (MN-11 cells): Pardaxin inhibited proliferation of MN-11 cells and reduced colony formation in soft agar assays . In a murine xenograft model, pardaxin treatment (25 mg/kg; 0.5 mg/day) for 14 days caused significant inhibition of MN-11 tumor growth compared to control groups .

• Human fibrosarcoma (HT1080 cells): Pardaxin inhibited colony formation and proliferation in HT1080 cells, suggesting potential application against human sarcomas .

• Human cervical cancer (HeLa cells): Pardaxin induced programmed cell death in HeLa cells, as evidenced by DNA fragmentation, increases in subG1 phase, and elevated caspase-8 activities .

These findings across multiple cancer cell types suggest Pardaxin-1 may have broad-spectrum antitumor activity, making it particularly interesting for applications against aggressive or resistant cancers. The peptide's demonstrated efficacy in both in vitro and in vivo models strengthens its potential as a novel anticancer agent.

Through what molecular mechanisms does Pardaxin-1 exert its antitumor effects?

Pardaxin-1 employs multiple molecular mechanisms to exert its antitumor effects:

• Membrane disruption: Transmission electron microscopy (TEM) has shown that Pardaxin alters membrane structure similar to lytic peptides, disrupting cancer cell membrane integrity .

• Apoptosis induction: Pardaxin treatment produces characteristic apoptotic features, including hollow mitochondria, nuclear condensation, and disrupted cell membranes .

• Death receptor/NF-κB signaling pathway: Quantitative RT-PCR and ELISA analyses demonstrated that Pardaxin treatment activates caspase-7 and interleukin (IL)-7r while downregulating caspase-9, ATF 3, SOCS3, STAT3, cathelicidin, p65, and interferon (IFN)-γ . This pattern suggests activation of the death receptor/nuclear factor (NF)-κB signaling pathway.

• Mitochondrial disruption: Pardaxin treatment disrupts mitochondrial membrane potential and increases reactive oxygen species (ROS) production in cancer cells, contributing to cell death .

• Anti-angiogenic effects: Pardaxin treatment inhibits tumor vascularization in vivo, potentially limiting tumor growth through reduced blood supply .

These diverse mechanisms suggest Pardaxin-1 could overcome resistance mechanisms that often develop against single-pathway targeted therapies, making it a promising candidate for combination or refractory cancer treatments.

What is the optimal dosing regimen for Pardaxin-1 in preclinical cancer models?

Based on available research data, the optimal dosing regimen for Pardaxin-1 in preclinical cancer models appears to be:

For in vivo murine fibrosarcoma models:

• Concentration: 25 mg/kg (equivalent to 0.5 mg/day for a 20g mouse)

• Administration schedule: Daily treatment

• Duration: 14 days

• Route of administration: Intratumoral injection

This dosing regimen resulted in significant inhibition of MN-11 cell growth in mice . After 14 days of treatment, substantial tumor volume reduction was observed compared to control groups. The effect was evident starting around day 7 of treatment.

For in vitro applications against cancer cells:

• Effective concentration: 13-17 μg/mL showed >90% inhibition of colony formation in MN-11 cells

• Exposure time: 24-hour treatment demonstrated significant inhibition of proliferation

It's important to note that optimal dosing may vary between different cancer types and models. Researchers should consider dose-escalation studies when applying Pardaxin-1 to new cancer models to establish tumor-specific optimal dosing regimens.

What techniques are most appropriate for assessing Pardaxin-1's membrane interactions?

Several complementary techniques have proven effective for comprehensively assessing Pardaxin-1's membrane interactions:

• Nuclear Magnetic Resonance (NMR) spectroscopy:

  • Transferred Nuclear Overhauser Effect Spectroscopy (tr-NOESY) for determining three-dimensional structure in membrane-bound states

  • Saturation Transfer Difference (STD) NMR for identifying specific residues that associate with membrane components like LPS

  • CPMG relaxation dispersion experiments for studying binding kinetics of Pardaxin-membrane complexes

  • ³¹P NMR for monitoring membrane disruption and lipid organization changes

• Biophysical methods:

  • Isothermal Titration Calorimetry (ITC) for determining binding thermodynamics (binding stoichiometry, association constants, enthalpy changes)

  • Dynamic Light Scattering (DLS) for assessing changes in membrane structure upon Pardaxin binding

  • Circular Dichroism (CD) spectroscopy for monitoring secondary structure changes in different membrane environments

  • Infrared (IR) spectroscopy for analyzing peptide-membrane interactions

• Membrane permeability assays:

  • Fluorescence-based assays using probes like N-phenyl-1-naphthylamine (NPN) to measure outer membrane permeabilization

  • Liposome-based leakage assays to quantify pore formation efficiency

These methodologies provide complementary insights into the complex mechanisms of Pardaxin-1's membrane interactions and can be selected based on the specific research question being addressed.

How can researchers effectively evaluate the antibacterial potency of Pardaxin-1?

To comprehensively evaluate the antibacterial potency of Pardaxin-1, researchers should employ a multi-faceted approach:

• Minimum Inhibitory Concentration (MIC) determination:

  • Broth microdilution method using standardized protocols (CLSI guidelines)

  • Testing against both gram-positive and gram-negative bacteria

  • Including reference antimicrobial peptides (melittin, magainin, cecropins) for comparative assessment

• Minimum Bactericidal Concentration (MBC) determination:

  • Subculturing from MIC assays onto antibiotic-free media

  • Determining the lowest concentration causing ≥99.9% killing

• Time-kill kinetics:

  • Monitoring bacterial viability over time at different Pardaxin-1 concentrations

  • Assessing concentration-dependent versus time-dependent killing patterns

• Membrane permeabilization assays:

  • Using fluorescent probes like propidium iodide or SYTOX Green for inner membrane disruption

  • Employing NPN fluorescence assays for outer membrane permeabilization of gram-negative bacteria

• Resistance development assessment:

  • Serial passage experiments with sub-inhibitory concentrations

  • Comparison of resistance development rates to conventional antibiotics

• Synergy testing:

  • Checkerboard assays with conventional antibiotics to determine fractional inhibitory concentration indices

  • Identifying potential combination therapies

This comprehensive approach provides a thorough characterization of Pardaxin-1's antibacterial properties and facilitates comparison with other antimicrobial agents.

What methodologies are most reliable for evaluating Pardaxin-1's antitumor effects?

A comprehensive assessment of Pardaxin-1's antitumor effects requires a multi-level approach:

• In vitro proliferation assays:

  • MTS/MTT assays at various concentrations (0-17 μg/mL) and time points (3, 6, 12, and 24 h) to determine dose and time-dependent effects

  • Colony formation assays in soft agar to assess long-term proliferation inhibition

• Cell death mechanism characterization:

  • Transmission electron microscopy (TEM) to visualize membrane and organelle structural changes

  • Flow cytometry for cell cycle analysis and quantification of subG1 populations

  • Annexin V/PI staining to distinguish between apoptosis and necrosis

  • TUNEL assay for DNA fragmentation assessment

• Molecular pathway analysis:

  • Quantitative RT-PCR for gene expression analysis of apoptosis-related genes (caspase-7, caspase-9, ATF3, SOCS3, STAT3, etc.)

  • ELISA for protein expression confirmation

  • Western blotting for key signaling proteins in death receptor/NF-κB pathways

  • Caspase activity assays (particularly caspase-3/7, -8, and -9)

• In vivo tumor models:

  • Subcutaneous xenograft models measuring tumor volume over time (e.g., 14-day treatment period)

  • Assessment of different dosing regimens (e.g., 25 mg/kg; 0.5 mg/day)

  • Histological analysis of tumor sections for apoptosis markers and vascularization

  • Immunohistochemistry for key pathway components

• Combination studies:

  • Testing Pardaxin-1 with established chemotherapeutic agents

  • Isobologram analysis to determine synergistic, additive, or antagonistic effects

This integrated approach provides robust evidence for antitumor activity while elucidating the underlying mechanisms of action.

How can researchers address the selectivity limitations of Pardaxin-1?

Addressing Pardaxin-1's selectivity limitations requires strategic approaches based on structure-activity relationships:

• Rational structural modifications:

  • C-terminal truncation: Removing 11 amino acids from the C-terminal domain substantially reduces hemolytic activity while maintaining antibacterial function

  • N-terminal positive charge addition: This modification increases antibacterial activity while eliminating hemolytic effects

  • Selective amidation: The aminated forms of specific domains show selective activity profiles that can be exploited for targeted applications

• Delivery system development:

  • Liposomal encapsulation to shield the peptide from non-target interactions

  • Tumor-targeting conjugation strategies using cancer-specific ligands

  • pH-sensitive release mechanisms to exploit the acidic tumor microenvironment

• Computational design approaches:

  • Molecular dynamics simulations to predict interactions with different membrane types

  • In silico screening of potential analogues before experimental validation

  • Quantitative structure-activity relationship (QSAR) modeling to guide precise modifications

• High-throughput screening:

  • Generation of Pardaxin-1 variant libraries through site-directed mutagenesis

  • Parallel screening against bacterial, cancer, and mammalian cell panels

  • Selection of candidates with optimal therapeutic indices

By combining these approaches, researchers can develop Pardaxin-1 variants with significantly enhanced selectivity profiles tailored to specific therapeutic applications, whether antimicrobial or anticancer.

What contradictions exist in the research literature regarding Pardaxin-1, and how might these be resolved?

Several notable contradictions exist in the Pardaxin-1 research literature that require resolution:

• Mechanism of action discrepancies:

  • Some studies suggest pardaxin forms stable pores, while others indicate transient membrane disruption without pore formation

  • Resolution approach: Conduct time-resolved biophysical studies using multiple membrane models and concentrations to establish a unified mechanistic model that accommodates context-dependent behaviors

• Structure-function relationship inconsistencies:

  • The LPS-bound "horseshoe" conformation differs significantly from structures in lipid micelles or organic solvents

  • Resolution approach: Perform comprehensive structural analyses across multiple membrane environments using complementary techniques (NMR, CD, computational modeling) to map conformation-function relationships

• Cell selectivity contradictions:

  • Native pardaxin shows reduced hemolytic activity compared to melittin, yet amidated pardaxin exhibits high hemolytic activity

  • Resolution approach: Conduct systematic structure-activity relationship studies with clearly defined experimental conditions to establish how specific modifications affect selectivity across different cell types

• Cancer cell death mechanism variations:

  • Different cancer cell lines show distinct death pathways (HeLa cells via caspase-8 activation versus HT1080 cells via mitochondrial disruption)

  • Resolution approach: Perform parallel pathway analyses across multiple cancer cell lines under identical conditions to develop a comprehensive model of cell-type dependent mechanisms

• Optimal dosing discrepancies:

  • Effective in vitro concentrations don't always translate to in vivo efficacy

  • Resolution approach: Establish pharmacokinetic/pharmacodynamic (PK/PD) models that bridge in vitro and in vivo findings through systematic dosing studies

Resolving these contradictions will require collaborative efforts employing standardized methodologies across laboratories and comprehensive reporting of experimental conditions.

What are the current limitations in producing recombinant Pardaxin-1 at research scale, and how might these be overcome?

Recombinant production of Pardaxin-1 faces several challenges that researchers must address:

• Cytotoxicity to expression hosts:

  • Challenge: Pardaxin-1's membrane-active properties can be toxic to bacterial or yeast expression systems

  • Solution: Utilize fusion protein strategies with solubility-enhancing partners (SUMO, thioredoxin, GST) and inducible expression systems with tight regulation

• Incorrect folding and aggregation:

  • Challenge: The amphipathic nature of Pardaxin-1 can lead to aggregation during expression

  • Solution: Optimize expression conditions (temperature, inducer concentration), incorporate chaperone co-expression, and use specialized E. coli strains designed for disulfide bond formation

• Proteolytic degradation:

  • Challenge: Host proteases may degrade the expressed peptide

  • Solution: Include protease inhibitors during purification, use protease-deficient host strains, and design constructs with strategic protease-resistant linkers

• Purification complexity:

  • Challenge: Separating the target peptide from cellular components while maintaining activity

  • Solution: Implement multi-step purification strategies (affinity chromatography, reverse-phase HPLC) and validate purified product activity at each step

• Scale-up limitations:

  • Challenge: Maintaining consistent quality during scale-up from small to medium research scales

  • Solution: Develop robust process parameters through design of experiments (DoE) approaches and implement quality-by-design principles

• Activity verification:

  • Challenge: Ensuring recombinant product has identical activity to synthetic or native peptide

  • Solution: Conduct comprehensive comparative characterization (structural, functional, stability) between recombinant and reference standards

By addressing these challenges systematically, researchers can establish reliable production platforms for recombinant Pardaxin-1 that yield consistent material for experimental applications.

What emerging applications of Pardaxin-1 warrant further investigation?

Several promising applications of Pardaxin-1 merit further research investment:

• Combination therapy approaches:

  • Integration with conventional antibiotics to combat resistant bacteria

  • Synergistic combinations with chemotherapeutic agents for enhanced tumor targeting

  • Exploration as an adjuvant to enhance immune responses to existing therapies

• Drug-resistant infection applications:

  • Activity against multidrug-resistant clinical isolates

  • Biofilm disruption capabilities

  • Prevention of resistance development compared to conventional antibiotics

• Cancer immunotherapy enhancement:

  • Investigation of immunomodulatory effects beyond direct cytotoxicity

  • Potential to stimulate anti-tumor immune responses

  • Combination with checkpoint inhibitors or CAR-T approaches

• Delivery system integration:

  • Incorporation into nanoparticle formulations for targeted delivery

  • Development of controlled-release systems for sustained activity

  • Design of stimulus-responsive delivery platforms (pH, temperature, enzyme)

• Wound healing applications:

  • Dual antimicrobial and tissue regeneration effects

  • Prevention of biofilm formation in chronic wounds

  • Development of Pardaxin-1-incorporated wound dressings

• Structure-based design of novel therapeutics:

  • Using Pardaxin-1's structural motifs as templates for synthetic antimicrobials

  • Developing peptidomimetics with enhanced stability and bioavailability

  • Creating hybrid molecules incorporating functional domains from Pardaxin-1

These emerging applications highlight the versatility of Pardaxin-1 as a platform for addressing multiple therapeutic challenges, particularly in the era of antimicrobial resistance and complex cancer treatment.

What technological advances would facilitate more detailed understanding of Pardaxin-1's mechanisms?

Advancing our understanding of Pardaxin-1 mechanisms requires cutting-edge technologies:

• Advanced structural biology techniques:

  • Cryo-electron microscopy to visualize membrane-peptide complexes at near-atomic resolution

  • Solid-state NMR with isotopically labeled Pardaxin-1 to characterize membrane-bound conformations

  • Single-molecule FRET to analyze peptide dynamics during membrane interactions

  • Advanced computational modeling with enhanced sampling techniques

• High-resolution cellular imaging:

  • Super-resolution microscopy to track Pardaxin-1 localization in real-time

  • Correlative light and electron microscopy to link functional effects with ultrastructural changes

  • Label-free imaging techniques to observe native peptide behavior without fluorophore interference

  • Multi-parameter live-cell imaging to simultaneously track multiple cellular responses

• Systems biology approaches:

  • Transcriptomics to comprehensively map gene expression changes in response to Pardaxin-1

  • Proteomics to identify the complete set of protein targets and pathway alterations

  • Metabolomics to characterize downstream metabolic effects

  • Network analysis to integrate multi-omics data into coherent mechanistic models

• Membrane biophysics innovations:

  • Nanodiscs and lipid bicelle systems for controlled membrane composition studies

  • Surface plasmon resonance with membrane mimetics for real-time binding kinetics

  • Atomic force microscopy to visualize peptide-induced membrane perturbations

  • Microfluidic systems for high-throughput membrane interaction screening

• Artificial intelligence integration:

  • Machine learning for predicting structure-activity relationships

  • Pattern recognition in complex datasets to identify subtle mechanistic signatures

  • Automated design of Pardaxin-1 variants with enhanced properties